Cdex, Inc. (fka CDEX)

[dw88in]

Press Release

CDEX Inc and London Imperial College Healthcare NHS Trust Announce Partnership Cooperation

UK's first Academic Health Science Centre incorporating London’s St Mary's and Hammersmith Hospitals, in partnership with Imperial College London to test ValiMed™ in clinical pharmacy settings and engage in new product development.

Tucson, Arizona and London, England – January 23, 2008 – CDEX Inc. (OTCBB: CEXI) follows up on recent announcements regarding international expansion by announcing today a partnership cooperation with the Imperial College Healthcare NHS Trust in London to test ValiMed in the Hammersmith and Charing Cross hospitals and to work together in developing new medication signatures including chemotherapy and cytostatic drugs. The ValiMed Medication Validation System uses Enhanced Photoemission Spectroscopy to quickly validate high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety. ValiMed compares a medication’s spectroscopic signature to the expected signature from the CDEX Medication Signature Library and returns an easy to understand “validated” or “not validated” result, requiring no user interpretation.

On January 7, 2008, CDEX announced publication of an 18 month independent study of the ValiMed™ Medication Validation System at the C.S. Mott Children's Hospital in the University of Michigan Health System in the American Journal of Health-System Pharmacists. “During the 18 months since [ValiMed] was implemented, five potentially serious medication errors have been detected and avoided,” the report stated. “[ValiMed] consistently validated the correct solution, while dependably detecting as invalid the wrong drug or concentrations that departed substantially from the targeted standard.” The press release from the University of Michigan can be accessed at http://www.ns.umich.edu/htdocs/releases/story.php?id=6255.

“We are delighted to have this opportunity to work in partnership with CDEX. By working in collaboration we will ensure product development is completely aligned with patient need to the mutual benefit of all,” said Professor Ann Jacklin, Chief Pharmacist at Hammersmith & Charing Cross hospitals, Imperial College Healthcare NHS Trust, and Visiting Professor at The School of Pharmacy University of London. In 2000 Ms. Jacklin initiated the formation of the Centre for Medicines Safety and Service Quality, a joint research centre between Hammersmith Hospital and the School of Pharmacy, and has been joint Chair of the centre since this time.

“We are honored that Professor Jacklin and her staff have elected to partner with CDEX in testing the ValiMed technology and developing new applications and signatures that will dramatically increase patient medications safety where it is most needed” said Malcolm Philips, CDEX President and CEO. “This marks another step in developing a global coalition of world class hospitals working together to address major medication delivery issues.”





About CDEX

CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (I) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (II) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is a CDEX solution for the healthcare market. Corporate headquarters and research and development facilities for CDEX are located in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com or contact CDEX, Inc. at 520.745.5172 or
[e-mail].

CDEX Inc.
Malcolm Philips or Stuart Poteet
520.745.5172
[e-mail]
[e-mail]


Any statements made in this press release, which contain information that is not historical, are essentially forward-looking. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks are detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.